Patent · US Active

Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods

US8486693B2 · kind B2 · utility

17Cited by
77References
24Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 19, 2012
Grant dateJul 16, 2013
Priority date—
Expiry dateSep 19, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2710/10343
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Modified antigen presenting cells provided herein have improved lifespan and immunogenicity compared to unmodified antigen presenting cells, and are useful for immunotherapy. The modified antigen presenting cells express an altered protein kinase, referred to herein as “Akt.” The altered Akt associates with the cell membrane with greater frequency than unaltered Akt, and is referred to herein as “membrane-targeted Akt.”

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.